Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
montelukast + mometasone furoate
- Development stage
- Phase 4
- Modality
- Small Molecules
- Administration
- Oral, Intranasal
01
Overview
A combination therapy consisting of montelukast, a leukotriene receptor antagonist, and mometasone furoate, a corticosteroid. This combination is primarily used for treating adenoid hypertrophy and allergic rhinitis. Montelukast works by selectively blocking leukotriene receptors to reduce inflammation, while mometasone furoate acts as a corticosteroid to suppress inflammatory responses in nasal tissues. Clinical studies have shown varying results regarding the efficacy of this combination compared to mometasone furoate monotherapy.
02
Targets
CYSLTR1 (Cysteinyl-leukotriene type 1 receptor)GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on montelukast + mometasone furoate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on montelukast + mometasone furoate.